Compare Ascendis Pharma A/S (ASND) vs Danaos Corporation (DAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Danaos Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Danaos Corporation trades at $128.39 (market cap $2.34B). The key difference: Ascendis Pharma A/S is far larger — about 7.6× Danaos Corporation's market cap, and Danaos Corporation pays a 2.8% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DAC | |
|---|---|---|
Market Cap | $17.74B | $2.34B |
Sector | Health | Technology |
52-Week High | $277.18 | $134.63 |
52-Week Low | $163.32 | $84.05 |
Enterprise Value | $18.11B | $2.34B |
Dividend Yield | — | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
DAC trades at $128.39, up 0.83% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 4.53, P/B of 0.6, and net income margin of 49.85%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while the company maintains a $0.90 quarterly dividend. Cash flow from operations remains robust at $645 million for 2025.
Outlook is positive given deep value metrics and high profitability, but risks include cyclical shipping demand and earnings volatility. Analyst consensus is mixed with 40% buy ratings. The stock offers value but requires monitoring of charter rate trends and global trade conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
